Compare MWG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWG | BLRX |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 12.6M |
| IPO Year | 2023 | 2011 |
| Metric | MWG | BLRX |
|---|---|---|
| Price | $0.27 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 15.6M | 27.2K |
| Earning Date | 12-23-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,413,000.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.48 | N/A |
| 52 Week Low | $0.21 | $2.30 |
| 52 Week High | $0.61 | $7.77 |
| Indicator | MWG | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 42.84 |
| Support Level | $0.25 | $2.71 |
| Resistance Level | $0.30 | $2.99 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.14 | 45.54 |
Multi Ways Holdings Ltd is a supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. The wide variety of new and used heavy construction equipment for sale and rental by customers range from: earth-moving equipment such as bulldozers, off-terrain dump trucks, excavators and wheel loaders; material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts and telescopic handlers; road-building equipment such as motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers and mini excavators; and generators and compressors, such as air compressors, generators, lighting towers and welding machines.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.